SCHEMBL17385995

SCHEMBL17385995

CCOCCOc1cc(C)c2c(c1)CCOc1ccc(C(=O)OC)cc1-2

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
FFAR1 O14842 10/20 0.39
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
KMT2A Q03164 1/20 0.36
THRA P10827 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17385996 0.90 FFAR1 (0.40) FFAR1MAPTTDP1L3MBTL1RAB9A
SCHEMBL17386246 0.87 TSHR (0.39) LMNAALDH1A1TSHRMAPK1FFAR1
SCHEMBL17385815 0.86 FFAR1 (0.44) ALDH1A1FFAR1MAPTTDP1L3MBTL1
SCHEMBL17385947 0.86 FFAR1 (0.41) LMNAALDH1A1TSHRMAPK1FFAR1
SCHEMBL17418007 0.86 TSHR (0.45) LMNAALDH1A1TSHRMAPK1MAPT
SCHEMBL17386041 0.85 MAPT (0.42) LMNAALDH1A1TSHRMAPK1MAPT
SCHEMBL17386086 0.85 FFAR1 (0.43) ALDH1A1FFAR1MAPTPOLBTDP1
SCHEMBL17385942 0.82 FFAR1 (0.39) FFAR1MEN1KMT2A
SCHEMBL17400081 0.82 KDM4E (0.41) LMNAALDH1A1TSHRMAPK1CYP2C9
SCHEMBL17417951 0.82 KDM4E (0.40) LMNAALDH1A1TSHRMAPK1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963027-B1 TRICYCLIC COMPOUND AND USE THEREOF TIUMBIO CO LTD (KR) 2018-12-26 EP disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 EP disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 LMNA 2845/4885ALDH1A1 2066/4885TSHR 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.